Price Alert

Dynavax Technologies Corp... (DVAX)

NASDAQ: DVAX · Real-Time Price · USD

10.62

-0.20 (-1.85%)

At close: Aug 14, 2025, 3:59 PM

10.45

-1.60%

After-hours: Aug 14, 2025, 07:34 PM EDT

-1.85% (1D)

Bid	9.82
Market Cap	1.25B
Revenue (ttm)	294.62M
Net Income (ttm)	-60.07M
EPS (ttm)	-0.45
PE Ratio (ttm)	-23.6
Forward PE	19.46
Analyst	Buy

Ask	12.8
Volume	849,330
Avg. Volume (20D)	1,757,846.9
Open	10.70
Previous Close	10.82
Day's Range	10.48 - 10.70
52-Week Range	9.22 - 14.63
Beta	1.09

About DVAX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DVAX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Dynavax has released their quartely earnings on Aug 7, 2025:

Revenue of $91.87M exceeds estimates by $4.85M, with 24.50% YoY growth.

EPS of 0.14 exceeds estimates by 0.01, with 75.00% YoY growth.

Next Earnings Release

Dynavax Technologies Corporation is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-10.99%

Dynavax Technologies shares are trading lower afte... Unlock content with Pro Subscription

4 months ago

-6.66%

Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.

News

4 days ago · seekingalpha.com

Dynavax Technologies: A Dip To Accumulate

Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and ...

1 week ago · seekingalpha.com

Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Sen...

1 week ago · zacks.com

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago.

1 week ago · fool.com

Dynavax (DVAX) Q2 Revenue Jumps 29%

2 months ago · reuters.com

Dynavax elects all four of its nominees after Deep Track proxy fight

Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.

2 months ago · businesswire.com

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...

Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Trac...

2 months ago · seekingalpha.com

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balance...